Disease · MONDO_0019781
astrocytoma (excluding glioblastoma)
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. astrocytoma (excluding glioblastoma). Diseases, record MONDO_0019781. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019781
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Astroglioma, astrocytic neoplasm, astrocytic tumor, astrocytoma, astrocytoma of brain, astrocytoma of cerebrum, astrocytoma, no ICD-O subtype
- Open Targets
- Highest stage of its drugs
- Approval, for 3 of its 48 drugs, from DailyMed, EMA Human Drugs and FDA
- Open Targets
Drugs48
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| VORASIDENIB | CHEMBL4279047 | Small molecule | Approval | EMA Human Drugs | 5 | 4 | 4 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets |
| CARMUSTINE | CHEMBL513 | Small molecule | Approval | DailyMed and FDA | 2 | 0 | 0 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| EFLORNITHINE | CHEMBL830 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LOMUSTINE | CHEMBL514 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SAFUSIDENIB | CHEMBL4651002 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ANTINEOPLASTON A10 | CHEMBL1980825 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 48
See all 48 drugsTargets81
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 3 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| PDE5A | 3',5'-cyclic phosphodiesterase | 3 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 5A inhibitor | Phase 1/2 | https://conductscience.org/library/genes/8654 | Drugs and targets |
| CD3D | T cell surface glycoprotein CD3 | 2 | T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 inhibitor | Phase 2 | https://conductscience.org/library/genes/915 | Drugs and targets |
| CD3E | T cell surface glycoprotein CD3 | 2 | T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 inhibitor | Phase 2 | https://conductscience.org/library/genes/916 | Drugs and targets |
| CD3G | T cell surface glycoprotein CD3 | 2 | T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 inhibitor | Phase 2 | https://conductscience.org/library/genes/917 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| IDH1 | IDH1/IDH2 | 2 | IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | Approval | https://conductscience.org/library/genes/3417 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 2 | Stem cell growth factor receptor inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 2 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
1 to 10 of 81
See all 81 targetsTrials50
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00626990 | Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH) | Phase 3 | 751 | 2023-09-11 | Brain and Central Nervous System Tumors | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00411619 | Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex | Phase 1/2 | 28 | 2014-10-20 | Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT03032484 | TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma | Phase 2 | 25 | 2023-06-15 | Astrocytoma | BEVACIZUMAB, DENIFANSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01188096 | A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas | Phase 2 | 23 | 2023-04-03 | Brain Tumors | HILTONOL | Its record names the disease | ClinicalTrials.gov |
| NCT00003468 | Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma | Phase 2 | 11 | 2016-11-10 | Low Grade Astrocytomas | ANTINEOPLASTON A10 | Its record names the disease | ClinicalTrials.gov |
| NCT00003471 | Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma | Phase 2 | 7 | 2017-12-13 | Low-Grade Astrocytoma, Nos | ANTINEOPLASTON A10 | Its record names the disease | ClinicalTrials.gov |
| NCT03906448 | FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma | Phase 2 | 1 | 2021-09-23 | Astrocytoma, Grade II, Astrocytoma, Grade III | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT07448480 | Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas | 1,000 | Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, Pleomorphic Xanthoastrocytoma | BEVACIZUMAB, CARBOPLATIN, IRINOTECAN, NIMUSTINE | Its record names the disease | ClinicalTrials.gov | ||
| NCT06809322 | Vorasidenib Maintenance for IDH Mutant Astrocytoma | Phase 3 | 468 | IDH-mutant Grade 2 or 3 Astrocytoma | VORASIDENIB | Its record names the disease | ClinicalTrials.gov | |
| NCT07215910 | Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | Phase 3 | 408 | Astrocytoma, IDH-Mutant, Grade 3 | TEMOZOLOMIDE, VORASIDENIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 50
See all 50 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials27
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019781
GET https://conductscience.org/api/diseases/v1/MONDO_0019781/drugs?page=2